Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer’s Disease

Sponsor:

Brief Summary:

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets
an abnormal protein in the brain found in people with Alzheimer’s Disease (AD).

Criteria

Inclusion Criteria:

– Participants must have gradual and progressive change in memory function for >6
months.

– Participants must have a family member or close friend who is with you at least 10
hours per week and can attend study appointments.

Exclusion Criteria:

– Participants must not have significant neurological disease affecting the nervous
system, other than AD, that affects cognition or may affect completion of the study.

– Participants must not have serious or unstable illness that could interfere with the
analysis of the study or has a life expectancy <24 months. - Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread. - Participants must not have serious risk for suicide. - Participants must not have history of drug or alcohol use disorder within the last 2 years. - Participants must not have multiple severe drug allergies - Participants must not have HIV, Hepatitis B or Hepatitis C - Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin (IVIG) therapy

Locations

Pharmacology Research Institute, Encino, California, United States, 91316
Fullerton Neurology and Headache Center, Fullerton, California, United States, 92835
Irvine Clinical Research Center, Irvine, California, United States, 92614
Pharmacology Research Institute, Los Alamitos, California, United States, 90720
National Research Institute – Huntington Park, Panorama City, California, United States, 91402
Anderson Clinical Research, Redlands, California, United States, 92374
Pacific Research Network, San Diego, California, United States, 92103
Univ of California San Francisco, San Francisco, California, United States, 94158
Syrentis Clinical Research, Santa Ana, California, United States, 92705